Lack of single agent activity is destined to failure in immunotherapy combo space. $RCHBY $MRK #TIGIT #IDO

$ONCT Updated Interim Data for Zilovertamab in Combo with Ibrutinib at ASCO 2022 MCL: - ORR of 85% (23/27 pts) VS 66% Ibrutinib mono - CR rate of 41% (11/27 pts) VS 20% for ibrutinib mono investor.oncternal.com/news-releases/…

Very rare you see mCR in treatment refractory patients and also this indication is one of the immunogenic cold tumor. Outstanding data, I hope there will be some recognition for this combo therapy.

Detailed comparison of NTLA-2001 and Alnylam's Nucresiran 1. Mechanism of Action: •NTLA-2001 $NTLA ◦In vivo CRISPR-Cas9 gene editing directly modifies the TTR gene, providing a one-time, potentially permanent treatment. ◦Aimed at halting disease progression by permanently

$NTLA 🧬📈🧬📈🧬📈 $128 - Buy - Jefferies - 11/18 $43 - Outperform - Bernstein - 11/18 $19 - Neutral - Citi - 11/18 $65 - Overweight - Cantor - 11/18 $90 - Buy - Canaccord - 11/18 $55 - Buy - Guggenheim - 11/18 $91 - Buy - Chardan - 11/18 $70 - Outperform - BMO - 11/17 $56 -

Congratulations Tesla team on a great year!

MY THOUGHTS ON CHINA'S DEEPSEEK MODEL China has plenty of incentives for Deepseek to lie about the cost of their AI open-source model (which they claim cost them just $6 million): 1) to convince American policymakers that GPU export controls have been ineffective at impeding

Repost to show the world we stand and support Elon Musk and Department of Government Efficiency

A new consensus is forming in China that FSD is at least a generation ahead, meaning that solutions from other car companies are outdated and ultimately unworkable.

$IOBT best ph3 1L melanoma PFS by a mile yet its tragic that market think path forward is challenging